What will Eli Lilly expect when reporting fourth-quarter earnings on Thursday? -Eli Lilly (NYSE: LLY)

Yili Lilly Liberal Its fourth quarter financial results for 2024 and 2025 financial guidance will be announced on February 6. Wall Street estimated sales of $13.7 billion and adjusted earnings per share of $4.94, according to Benzinga Pro.

In January, just ahead of the JP Morgan Healthcare meeting, Eli Lilly announced that it expected full-year revenue of about $45 billion for 2024, a 32% increase from the previous year, compared to the $455 billion consensus.

The company expects revenue for 2024 to be $400 million, about 3%, below the guidance range for the issuance during the third-quarter earnings period. The guide includes about $3.5 billion for Mounjaro and $1.9 billion for Zepbough.

Also read: Big Pharma is about to win? Goldman Sachs weigh 340B and Medicaid shifts

Analysts are tracking Eli Lilly’s expected increase in sales and profits in the first quarter, during which its weight loss pills are no longer lacking.

In October 2024, the FDA determined that Eli Lilly’s Tirzepatide injection shortage was resolved.

The U.S. pharmaceutical giant reported revenue in the third quarter of $11.44 billion, a year-on-year increase of 20%, but missed a consensus of $121.1 billion. Mounjaro sales more than doubled from $1.41 billion a year ago to $31.1 billion.

Sales of Verzenio, a breast cancer drug, rose 32% to $1.37 billion, while sales of diabetes drugs fell 2% to $686.4 million.

Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to $1.3 billion.

Rival Novo Nordisk A/s NVO Stocks trade higher. On Wednesday, the company reported sales of approximately $12.25 billion (85.68 billion Denmark Krona) in the fourth quarter of 2024, surpassing the consensus of $11.34 billion (797.3 billion Denmark Krona).

Sales of GLP-1 diabetes increased by 12%, while sales of obesity care increased by 91%.

Ozempic’s sales rose 12% to 3.85 billion Denmark Krona, while Wegovy’s sales doubled to 19.87 billion Denmark Krona.

According to Reuters, investors and analysts expect Eli Lilly to outline its strategy to promote Zepbough this year as it aims to compete with the more mature drug Wegovy.

According to IQVIA data cited by analysts, Zepbound accounts for more than 50% of the market. Eli Lilly began promoting the drug in November.

Price action: Lly shares rose 2.19% to $843.59 in the last check on Wednesday.

Read the next post:

Image of Mohammed_al_ali through shutterstock